REGN Regeneron Pharmaceuticals, Inc.

Price (delayed)

$610.89

Market cap

$64.99B

P/E Ratio

22.41

Dividend/share

N/A

EPS

$27.26

Enterprise value

$65.22B

Sector: Healthcare
Industry: Biotechnology
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.

Highlights

Regeneron Pharmaceuticals's net income has increased by 44% YoY and by 31% QoQ
The company's EPS rose by 43% YoY and by 31% QoQ
REGN's price to earnings (P/E) is 38% lower than its 5-year quarterly average of 36.4 but 13% higher than its last 4 quarters average of 19.9
The quick ratio has plunged by 52% from the previous quarter and by 46% YoY
The equity has declined by 25% since the previous quarter and by 7% year-on-year

Key stats

What are the main financial stats of REGN
Market
Shares outstanding
106.39M
Market cap
$64.99B
Enterprise value
$65.22B
Valuations
Price to earnings (P/E)
22.41
Price to book (P/B)
7.59
Price to sales (P/S)
8.37
EV/EBIT
19.91
EV/EBITDA
18.64
EV/Sales
8.15
Earnings
Revenue
$8B
EBIT
$3.28B
EBITDA
$3.5B
Free cash flow
$2.43B
Per share
EPS
$27.26
Free cash flow per share
$22.13
Book value per share
$80.49
Revenue per share
$72.98
TBVPS
$131.65
Balance sheet
Total assets
$14.43B
Total liabilities
$5.37B
Debt
$2.22B
Equity
$9.06B
Working capital
$4.16B
Liquidity
Debt to equity
0.24
Current ratio
2.12
Quick ratio
1.61
Net debt/EBITDA
0.06
Margins
EBITDA margin
43.7%
Gross margin
88.2%
Net margin
37.3%
Operating margin
34.6%
Efficiency
Return on assets
20.3%
Return on equity
27.9%
Return on invested capital
28.2%
Return on capital employed
30.5%
Return on sales
41%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

REGN stock price

How has the Regeneron Pharmaceuticals stock price performed over time

Financial performance

How have Regeneron Pharmaceuticals's revenue and profit performed over time
Revenue
$8B
Gross profit
$7.05B
Operating income
$2.77B
Net income
$2.98B
Gross margin
88.2%
Net margin
37.3%
Regeneron Pharmaceuticals's net income has increased by 44% YoY and by 31% QoQ
The operating income rose by 29% YoY and by 14% QoQ
The net margin has increased by 25% from the previous quarter and by 18% YoY
The revenue has increased by 22% YoY and by 4.9% QoQ

Valuation

What is Regeneron Pharmaceuticals stock price valuation
P/E
22.41
P/B
7.59
P/S
8.37
EV/EBIT
19.91
EV/EBITDA
18.64
EV/Sales
8.15
The company's EPS rose by 43% YoY and by 31% QoQ
REGN's price to earnings (P/E) is 38% lower than its 5-year quarterly average of 36.4 but 13% higher than its last 4 quarters average of 19.9
REGN's price to book (P/B) is 62% more than its last 4 quarters average of 4.7 and 2.6% more than its 5-year quarterly average of 7.4
The equity has declined by 25% since the previous quarter and by 7% year-on-year
The P/S is 33% higher than the last 4 quarters average of 6.3 and 7% higher than the 5-year quarterly average of 7.8
The revenue has increased by 22% YoY and by 4.9% QoQ

Efficiency

How efficient is Regeneron Pharmaceuticals business performance
Regeneron Pharmaceuticals's return on invested capital has increased by 34% YoY and by 28% QoQ
Regeneron Pharmaceuticals's return on equity has increased by 33% QoQ and by 21% YoY
The return on assets has increased by 29% since the previous quarter and by 19% year-on-year
The company's return on sales rose by 27% YoY and by 21% QoQ

Dividends

What is REGN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for REGN.

Financial health

How did Regeneron Pharmaceuticals financials performed over time
REGN's total assets is 169% greater than its total liabilities
Regeneron Pharmaceuticals's total liabilities has surged by 57% YoY and by 48% QoQ
The quick ratio has plunged by 52% from the previous quarter and by 46% YoY
The debt is 76% less than the equity
The equity has declined by 25% since the previous quarter and by 7% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.